title: Radioimmunotherapy confers long-term survival to lymphoma patients with acceptable toxicity: registry analysis by the International Radioimmunotherapy Network.
abstract: The Radioimmunotherapy Network (RIT-N) is a Web-based, international registry collecting long-term observational data about radioimmunotherapy-treated patients with malignant lymphoma outside randomized clinical studies. The RIT-N collects unbiased data on treatment indications, disease stages, patients' conditions, lymphoma subtypes, and hematologic side effects of radioimmunotherapy treatment.
  
  
  METHODS
  RIT-N is located at the University of Göttingen, Germany, and collected data from 14 countries. Data were entered by investigators into a Web-based central database managed by an independent clinical research organization.
  
  
  RESULTS
  Patients (1,075) were enrolled from December 2006 until November 2009, and 467 patients with an observation time of at least 12 mo were included in the following analysis. Diagnoses were as follows: 58% follicular lymphoma and 42% other B-cell lymphomas. The mean overall survival was 28 mo for follicular lymphoma and 26 mo for other lymphoma subtypes. Hematotoxicity was mild for hemoglobin (World Health Organization grade II), with a median nadir of 10 g/dL, but severe (World Health Organization grade III) for platelets and leukocytes, with a median nadir of 7,000/μL and 2.2/μL, respectively.
  
  
  CONCLUSIONS
  Clinical usage of radioimmunotherapy differs from the labeled indications and can be assessed by this registry, enabling analyses of outcome and toxicity data beyond clinical trials. This analysis proves that radioimmunotherapy in follicular lymphoma and other lymphoma subtypes is a safe and efficient treatment option.
authors.affiliation: Göttingen Comprehensive Cancer Center, Georg August University, Göttingen, Germany. karo.hohloch@med.uni-goettingen.de
authors.forename: Karin
authors.initials: K
authors.lastname: Hohloch
authors.forename: Angelika Bischof
authors.initials: AB
authors.lastname: Delaloye
authors.forename: Christiane
authors.initials: C
authors.lastname: Windemuth-Kieselbach
authors.forename: Jose
authors.initials: J
authors.lastname: Gómez-Codina
authors.forename: Werner
authors.initials: W
authors.lastname: Linkesch
authors.forename: Woijciech
authors.initials: W
authors.lastname: Jurczak
authors.forename: Roberto
authors.initials: R
authors.lastname: Cacchione
authors.forename: Cheolwon
authors.initials: C
authors.lastname: Suh
authors.forename: Pier Luigi
authors.initials: PL
authors.lastname: Zinzani
authors.forename: Lorenz
authors.initials: L
authors.lastname: Trümper
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001853:Bone Marrow / Q000473:pathology; D003628:Database Management Systems; D016208:Databases, Factual; D018450:Disease Progression; D005260:Female; D006402:Hematologic Diseases / Q000209:etiology; D006801:Humans; D020407:Internet; D008223:Lymphoma / Q000473:pathology / Q000532:radiotherapy*; D008224:Lymphoma, Follicular / Q000473:pathology / Q000532:radiotherapy; D008297:Male; D008875:Middle Aged; D016499:Radioimmunotherapy / Q000009:adverse effects / Q000706:statistics & numerical data*; D019275:Radiopharmaceuticals / Q000627:therapeutic use; D012042:Registries; D033581:Stem Cell Transplantation; D013534:Survival; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000911:Antibodies, Monoclonal; D019275:Radiopharmaceuticals; C422802:ibritumomab tiuxetan